Artritis reumatoide: actitudes terapéuticas

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation and progressive damage. The goal of RA treatment is to eliminate inflammation so as to avoid irreversible joint damage and the resulting disability. The key to achieving this is early initiation in the first weeks after diagnosis (“therapeutic window”) and the treat-to-target strategy, which focuses on continuously adjusting treatment to achieve specific goals: remission or low disease activity. Conventional disease-modifying drugs (DMARDs), such as methotrexate, continue to be the first line of treatment. However, the therapeutic arsenal has grown considerably in recent years, with a wide range of targeted biologic and synthetic DMARDs (JAK inhibitors) now available. This allows therapy to be personalized according to each patient's response and to achieve objectives more effectively.